(Reuters) -AstraZeneca (AZN) plans to directly list its shares on the New York Stock Exchange, instead of its current depositary receipts structure, to attract more global investors, the drugmaker said on Monday, but will remain listed and headquartered in London. The move will be of some relief to UK investors after media reports suggested the Anglo-Swedish drugmaker - London's most valuable company - was considering ditching its British listing in favour of the U.S. That had raised worries about the shr ...